annual general meeting, fresenius se & co. kgaa · seite 2 2014 group results cc = constand...
TRANSCRIPT
Annual General Meeting, Fresenius SE & Co. KGaA
May 20, 2015
Seite 2
2014 Group results
cc = constand currencyEBIT and net income before one-time items
Sales EBIT Net income
Financial Year 2014 €23,231 m €3,158 m €1,086 m
Growth cc +16% +4% +4%
Growth actual rates +14% +4% +3%
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
Seite 3
7.37.9
10.811.4
12.3
14.2
16.0 16.5
19.320.3
23.2
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Sales
11th consecutive record year
€bn
168222
330
410450
514
660
770
938
1.0511.086
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
€bn
Sales Net Income
CAGR 12 % CAGR 21 %
CAGR = annual growth rateNet income before one-time items
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
Seite 4
2014 results for the business segments
FY 2014
SalesUS$15,832 m
+8%€5,146 m
+3%€5,244 m
+55%€1,042 m
+2%
EBITUS$2,255 m
+0%€873 m
-6%€553 m+42%
€59 m+7%
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
Seite 5
Fresenius Group:An excellent start to the new business year
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Sales EBIT Net income
Q1/15 €6,483 m €851 m €292 m
Growth cc +13% +18% +16%
Growth actual rates +24% +32% +28%
cc = constand currencyEBIT and net income before one-time items
Page
Seite 6
0.020.04 0.04
0.05 0.060.07
0.090.10
0.110.13
0.140.15
0.16
0.19
0.220.23
0.25
0.29
0.32
0.37
0.42
0.44
93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14
22nd consecutive dividend increase
Pay-out ratio: 22%
2014: Proposal1993 – 2013: stock split-adjusted
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
In €
Seite 7
The Fresenius share: An attractive long-term investment
0 4 8 12 16 20 24
DAX30
Fresenius share ~20% p.a.
~9% p.a.
%
Compounded annual total return Dec 31, 2004 − Dec 31, 2014
Source: Bloomberg; dividends reinvested
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
Seite 8Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Continuity as an integral part of our corporate culture
Page
Seite 9
Continuity in our values
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Patient focus Quality
Reliability Innovation
Page
Seite 10Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Continuity through long-term strategies:Acquisition of Rhön hospitals
HELIOS 2013
Page
HELIOS 2015
Seite 11Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Continuity through long-term strategies:Fresenius in emerging markets
Page
Seite 12Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Continuity through long-term strategies:From products to therapies
Page
Seite 13Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Our responsibility
Page
Seite 14Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Continuity in management and staff
Page
“Team Fresenius” at the JP Morgan Run in Frankfurt, Germany
Seite 15Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
Steadily increasing demand for healthcare
Page
Seite 16
Outlook for 2015: Fresenius raises guidance
Old New
Revenuein constant currency
+7% to +10%
Net incomein constant currency
+9% to +12% +13% to +16%
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG (~€10 m before tax), before costs for efficiencyprogram at Fresenius Kabi (~€100 m before tax) and disposal gains from the divestment of two HELIOS hospitals (€34 m before tax); 2014 before special items
Page
Seite 17
Fresenius confirms medium-term targets
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015
20.3
23.2
2013 2014 2017
1,0511,086
2013 2014 2017
Sales€bn
Net Income1
€m
1 Before special items
~€30 billion Sales; €1.4 to €1.5 billion Net Income
CAGR 9-11%CAGR 9%~30
~1,400-1,500
+14%
+3%
Page
Seite 18
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page
Annual General Meeting, Fresenius SE & Co. KGaA
May 20, 2015